Boehringer Ingelheim Fremont Inc.
6701 Kaiser Drive
About Boehringer Ingelheim Fremont Inc.
Boehringer Ingelheim Fremont Inc. is part of Boehringer Ingelheim BioXcellence™, a leading biopharmaceutical contract manufacturer. As mammalian cell culture center in the heart of Silicon Valley more than 500 scientist and specialists are committed to research, development and manufacturing to make high quality medicines for patients.
Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and fully continuous manufacturing. With the complete range of services, from cell line and strain development including high expression systems through process development and large-scale manufacturing to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Boehringer Ingelheim BioXcellence™ has over 35 years of biotechnology experience, more than 3,600 dedicated and highly trained employees. With our global network we have helped customers to bring more than 30 molecules to the market. Our network of facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China for manufacturing in mammalian cell culture and microorganisms.
We are one integrated global team with one shared passion: Your product.
Biopharmaceuticals - Competence and Experience for Medicines of the Future
Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
943 articles with Boehringer Ingelheim Fremont Inc.
10/21/2019Last week was busy for clinical trial news. Here’s a look.
9/9/2019The U.S. Food and Drug Administration (FDA) gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
8/30/2019Biopharma companies strengthen their leadership and boards with these appointments.
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of almost four years (45.7 months) in patients with Del19-positive tumors
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
Boehringer Ingelheim announced that the FDA's Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev® (nintedanib) for the treatment of systemic sclerosis associated interstitial lung disease, or SSc-ILD.
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met
Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers
The M&A moves are expected to increase the oncology pipelines of both companies.
Boehringer Ingelheim announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.
7/3/2019Companies from across the globe provide information on agreements and pipeline updates.
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
The U.S. Food and Drug Administration has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced.
Arizona Care Network Partners with Solve.Care, Pharmaceutical Leader Boehringer Ingelheim To Launch Diabetes Care Administration Network
New Care.Wallet app will help patients proactively address risks and symptoms of diabetes
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines
Here’s a roundup of some of the top clinical trial news from the previous week.
Germany-based Boehringer Ingelheim announced that its SENSCIS Phase III clinical trial met its primary endpoint, which was reduction in the annual rate of decline in forced vital capacity.